



## Corporate Profile

Seikagaku Corporation is a leader in the expanding field of glycoscience, a discipline that involves the study of glycoconjugates—complex, hybrid macromolecules of carbohydrate and non-carbohydrate composition that serve to control all of life’s basic processes. In 1950, Seikagaku was the first company to manufacture chondroitin sulfate on an industrial scale, and this glycoconjugate is now an essential component of a wide variety of pharmaceutical products. In 1987, it launched the world’s first sodium hyaluronate formulation for osteoarthritis in knee and shoulder joints, which it sells under the ARTZ®, ARTZAL® and SUPARTZ® brands throughout the world.

Today, Seikagaku is recognized internationally as a primary producer of glycoconjugate-related pharmaceuticals, such as sodium hyaluronate formulations for osteoarthritis, along with OPEGAN® and OPEGAN Hi®, which were Japan’s first sodium hyaluronate formulations used as a surgical aid in cataract surgery.

A very important area of Seikagaku’s business includes ethical pharmaceuticals, along with research biologicals and diagnostics that are used for glycoconjugate research and medical treatment. The sale of pharmaceutical bulk products also comprises a part of Seikagaku’s operations.

Seikagaku has a vision: to realize, on behalf of patients and medical professionals, the full promise inherent in the field of glycoscience, which after 50 years of support, is finally emerging as a venue of leading-edge scientific and clinical inquiry.

### Seikagaku’s Business Outline



### Contents

Glycoscience .....	1
A Message from the President ...	2
Consolidated Financial Highlights .....	2
R&D Activities and Production Facilities .....	5
Divisional Review .....	6
Organization .....	7
Financial Statements .....	8
Corporate Data .....	19